デフォルト表紙
市場調査レポート
商品コード
1493293

幹細胞治療の市場規模、シェア、動向分析レポート:治療タイプ別、治療用途別、地域別、セグメント予測、2024年~2030年

Stem Cell Therapy Market Size, Share & Trends Analysis Report By Therapy Type, By Therapeutic Application (Oncology, Cardiovascular Disease, Musculoskeletal Disorders), By Region, And Segment Forecasts, 2024 - 2030

出版日: | 発行: Grand View Research | ページ情報: 英文 100 Pages | 納期: 2~10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=159.45円
幹細胞治療の市場規模、シェア、動向分析レポート:治療タイプ別、治療用途別、地域別、セグメント予測、2024年~2030年
出版日: 2024年05月22日
発行: Grand View Research
ページ情報: 英文 100 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

幹細胞治療市場の成長と動向:

Grand View Research, Inc.の最新レポートによると、世界の幹細胞治療市場規模は2030年までに16億7,010万米ドルに達すると予測され、2024年から2030年までのCAGRは24.15%で成長すると予測されています。

幹細胞研究と技術の進歩は、再生医療の展望に革命をもたらしました。幹細胞の単離、特性解析、操作技術における飛躍的な進歩により、研究者たちは幹細胞の治療可能性をより正確に、より効果的に活用できるようになりました。例えば、2023年5月、EPROCELLは間葉系幹細胞(MSC)由来の先進治療薬(ATMP)を製造するための開発・製造受託機関(CDMO)サービスを導入しました。この拡大はHistocell社との提携によって促進されています。このような進歩は、慢性疾患から変性疾患まで、幅広い病状を対象とした革新的な治療法の開発に拍車をかけています。

慢性疾患や退行性疾患の有病率の増加は、新規治療法に対する需要を煽っています。心血管疾患、神経変性疾患、整形外科的損傷、自己免疫疾患などの病態は、ヘルスケアに重大な課題をもたらし、革新的な治療アプローチの探求を後押ししています。例えば、Lancet Neurology誌に掲載された研究では、2040年までにパーキンソン病に罹患する人の数が大幅に増加すると予測されています。この予測数値は、この神経変性疾患を患う人の数が倍増し、世界中で少なくとも1,290万人に達する可能性を示唆しており、憂慮すべきものです。幹細胞治療は、組織再生の促進、免疫反応の調節、臓器機能の回復など、これらの複雑な疾患に対処する上で非常に有望であり、疾患管理と治療に新たな道を提供します。

投資家が画期的な医学的進歩と有利なリターンの可能性を認識しているため、世界市場への投資は着実に増加しています。このような資金の流入は、研究、開発、商業化の努力を促進し、市場全体の成長を牽引しています。再生医療と個別化ヘルスケアが重視されるようになったことで、同市場は今後も拡大を続け、革新的な治療法と新たな希望を、さまざまな病状と闘う患者に提供する態勢が整いつつあります。

幹細胞治療市場のレポートハイライト

  • 治療タイプ別では、同種幹細胞治療分野が2023年までに68.41%の収益シェアで市場をリードし、予測期間中は26.74%のCAGRで最速の成長が見込まれます。
  • 治療用途に基づくと、血液疾患や神経疾患などの疾患を含むその他の治療分野は、進行中の研究や臨床の進歩に後押しされ、2023年に72.75%の最大の売上高シェアで市場をリードしました。
  • 北米は、2023年に50.11%の最大収益シェアで市場を独占し、いくつかの重要な要因によって、予測期間中に28.07%の最速CAGRで成長すると予測されています。市場の成長は、有利な規制の枠組み、慢性疾患の割合の上昇、技術の向上によって促進されます。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/補助市場見通し
  • 市場力学
    • 市場 促進要因分析
    • 市場抑制要因分析
  • 業界分析ツール
    • ポーターのファイブフォース分析
    • PESTEL分析
    • COVID-19の影響分析

第4章 幹細胞治療市場:治療タイプ別ビジネス分析

  • セグメントダッシュボード
  • 世界の幹細胞治療市場治療タイプの変動分析
  • 世界の幹細胞治療市場規模と動向分析、治療タイプ別、2018~2030年
  • 同種幹細胞療法
  • 自己幹細胞療法

第5章 幹細胞治療市場:治療用途別ビジネス分析

  • セグメントダッシュボード
  • 世界の幹細胞治療市場の治療用途、変動分析
  • 世界の幹細胞治療市場規模と動向分析、治療用途別、2018~2030年
  • 腫瘍学
  • 心血管疾患(CVD)
  • 筋骨格障害
  • その他

第6章 幹細胞治療市場:治療タイプと治療用途別の地域推定・動向分析

  • 地域ダッシュボード
  • 市場規模と予測および動向分析、2018年から2030年
  • 北米
  • 欧州
  • アジア太平洋地域
  • 世界のその他の地域

第7章 競合情勢

  • 参入企業
  • 戦略マッピング
  • 企業市況分析、2023年
  • 参入企業の概要
    • Bluebird Bio, Inc.
    • NIPRO
    • Orchard Therapeutics plc
    • Pharmicell Co., Ltd.
    • CorestemChemon Inc.
    • ANTEROGEN.CO.,LTD.
    • Holostem Srl
    • Vertex Pharmaceuticals, Inc.
    • Cleveland Cord Blood Center
    • Gamida Cell Ltd.
図表

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global stem cell therapy market, by therapy type, 2018 - 2030 (USD Million)
  • Table 4 Global stem cell therapy market, by application, 2018 - 2030 (USD Million)
  • Table 5 Global stem cell therapy market, by region, 2018 - 2030 (USD Million)
  • Table 6 North America stem cell therapy market, by country, 2018 - 2030 (USD Million)
  • Table 7 North America stem cell therapy market, by therapy type, 2018 - 2030 (USD Million)
  • Table 8 North America stem cell therapy market, by therapeutical application, 2018 - 2030 (USD Million)
  • Table 9 U.S. stem cell therapy market, by therapy type, 2018 - 2030 (USD Million)
  • Table 10 U.S. stem cell therapy market, by therapeutical application, 2018 - 2030 (USD Million)
  • Table 11 U.S. stem cell therapy market, by end-use, 2018 - 2030 (USD Million)
  • Table 12 Canada stem cell therapy market, by therapy type, 2018 - 2030 (USD Million)
  • Table 13 Canada stem cell therapy market, by therapeutical application, 2018 - 2030 (USD Million)
  • Table 14 Europe stem cell therapy market, by country, 2018 - 2030 (USD Million)
  • Table 15 Europe stem cell therapy market, by therapy type, 2018 - 2030 (USD Million)
  • Table 16 Europe stem cell therapy market, by therapeutical application, 2018 - 2030 (USD Million)
  • Table 17 UK stem cell therapy market, by therapy type, 2018 - 2030 (USD Million)
  • Table 18 UK stem cell therapy market, by therapeutical application, 2018 - 2030 (USD Million)
  • Table 19 Germany stem cell therapy market, by therapy type, 2018 - 2030 (USD Million)
  • Table 20 Germany stem cell therapy market, by therapeutical application, 2018 - 2030 (USD Million)
  • Table 21 Switzerland stem cell therapy market, by therapy type, 2018 - 2030 (USD Million)
  • Table 22 Switzerland stem cell therapy market, by therapeutical application, 2018 - 2030 (USD Million)
  • Table 23 Asia Pacific stem cell therapy market, by country, 2018 - 2030 (USD Million)
  • Table 24 Asia Pacific stem cell therapy market, by therapy type, 2018 - 2030 (USD Million)
  • Table 25 Asia Pacific stem cell therapy market, by therapeutical application, 2018 - 2030 (USD Million)
  • Table 26 Japan stem cell therapy market, by therapy type, 2018 - 2030 (USD Million)
  • Table 27 Japan stem cell therapy market, by therapeutical application, 2018 - 2030 (USD Million)
  • Table 28 China stem cell therapy market, by therapy type, 2018 - 2030 (USD Million)
  • Table 29 China stem cell therapy market, by therapeutical application, 2018 - 2030 (USD Million)
  • Table 30 India stem cell therapy market, by therapy type, 2018 - 2030 (USD Million)
  • Table 31 India stem cell therapy market, by therapeutical application, 2018 - 2030 (USD Million)
  • Table 32 South Korea stem cell therapy market, by therapy type, 2018 - 2030 (USD Million)
  • Table 33 South Korea stem cell therapy market, by therapeutical application, 2018 - 2030 (USD Million)
  • Table 34 Rest of World stem cell therapy market, by therapy type, 2018 - 2030 (USD Million)
  • Table 35 Rest of World stem cell therapy market, by therapeutical application, 2018 - 2030 (USD Million)
  • Table 36 Participant's overview
  • Table 37 Financial performance
  • Table 38 Key companies undergoing expansions
  • Table 39 Key companies undergoing acquisitions
  • Table 40 Key companies undergoing collaborations
  • Table 41 Key companies launching new products
  • Table 42 Key companies undertaking other strategies

List of Figures

  • Fig. 1 Stem cell therapy market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Market formulation & validation
  • Fig. 7 Market outlook
  • Fig. 8 Segment snapshot
  • Fig. 9 Competitive landscape snapshot
  • Fig. 10 Parent market outlook
  • Fig. 11 Stem cell therapy market driver analysis
  • Fig. 12 Stem cell therapy market restraint analysis
  • Fig. 13 Stem cell therapy market: Porter's analysis
  • Fig. 14 Stem cell therapy market: PESTEL analysis
  • Fig. 15 Stem cell therapy market: Therapy type outlook and key takeaways
  • Fig. 16 Stem cell therapy market: Therapy type market share analysis, 2023 - 2030
  • Fig. 17 Global stem cell therapy by allogeneic stem cell therapies market, 2018 - 2030 (USD Million)
  • Fig. 18 Global stem cell therapy by hematopoietic stem cell therapies market, 2018 - 2030 (USD Million)
  • Fig. 19 Global stem cell therapy by mesenchymal stem cell therapies market, 2018 - 2030 (USD Million)
  • Fig. 20 Global stem cell therapy by autologous stem cell therapies market, 2018 - 2030 (USD Million)
  • Fig. 21 Global stem cell therapy by BM, blood, & umbilical cord-derived stem cells market, 2018 - 2030 (USD Million)
  • Fig. 22 Global stem cell therapy by adipose derived cells market, 2018 - 2030 (USD Million)
  • Fig. 23 Global stem cell therapy by others market, 2018 - 2030 (USD Million)
  • Fig. 24 Stem cell therapy market: Therapeutical application outlook and key takeaways
  • Fig. 25 Stem cell therapy market: Therapeutical application market share analysis, 2023-2030
  • Fig. 26 Global stem cell therapy by oncology market, 2018 - 2030 (USD Million)
  • Fig. 27 Global stem cell therapy by cardiovascular disease (CVD) market, 2018 - 2030 (USD Million)
  • Fig. 28 Global stem cell therapy by musculoskeletal disorders market, 2018 - 2030 (USD Million)
  • Fig. 29 Global stem cell therapy by other market, 2018 - 2030 (USD Million)
  • Fig. 30 Regional marketplace: Key takeaways
  • Fig. 31 North America stem cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 U.S. stem cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Canada stem cell therapy market, 2018 - 2030 (USD Million)
  • Fig. 34 Europe stem cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 UK stem cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Germany stem cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Switzerland stem cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Asia-Pacific stem cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 39 Japan stem cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 40 China stem cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 41 India stem cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 South Korea stem cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 43 Rest of World stem cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 44 Key company categorization
  • Fig. 45 Company market positioning
  • Fig. 46 Market participant categorization
  • Fig. 47 Strategy framework
目次
Product Code: GVR-4-68040-274-4

Stem Cell Therapy Market Growth & Trends:

The global stem cell therapy market size is anticipated to reach USD 1,670.1 million by 2030 and is projected to grow at a CAGR of 24.15% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market growth is propelled by several key factors that underscore both scientific advancements and evolving healthcare needs.Advancements in stem cell research and technology have revolutionized the landscape of regenerative medicine. Breakthroughs in stem cell isolation, characterization, and manipulation techniques have empowered researchers to harness the therapeutic potential of stem cells with greater precision and efficacy. For instance, in May 2023, EPROCELL introduced Contract Development and Manufacturing Organization (CDMO) services for producing Advanced Therapies Medicinal Products (ATMPs) derived from mesenchymal stem cells (MSC). This expansion is facilitated by a partnership with Histocell. These advancements have spurred the development of innovative therapies targeting a wide spectrum of medical conditions, from chronic diseases to degenerative disorders.

The increasing prevalence of chronic and degenerative diseases has fueled the demand for novel treatment modalities. Conditions such as cardiovascular diseases, neurodegenerative disorders, orthopedic injuries, and autoimmune diseases pose significant healthcare challenges, driving the search for innovative therapeutic approaches. For instance, a study published in The Lancet Neurology has anticipated a significant increase in the number of individuals affected by Parkinson's disease by the year 2040. The projected figure is alarming, as it suggests that the number of people living with this neurodegenerative disorder may double, reaching at least 12.9 million worldwide. Stem cell therapies hold immense promise in addressing these complex diseases by promoting tissue regeneration, modulating immune responses, and restoring organ function, thus offering new avenues for disease management and treatment.

Investment in the global market has been steadily increasing as investors recognize the potential for groundbreaking medical advancements and lucrative returns. This influx of capital fuels research, development, and commercialization efforts, driving the overall market growth. With a growing emphasis on regenerative medicine and personalized healthcare, the market is poised for continued expansion, offering innovative treatments and renewed hope to patients grappling with a wide range of medical conditions.

Stem Cell Therapy Market Report Highlights:

  • Based on therapy type, the allogeneic stem cell therapies segment led the market with the largest revenue share of 68.41% by 2023 and is anticipated to grow at the fastest CAGR of 26.74% during the forecast period, propelled by a convergence of factors contributing to its expansion such as increasing landscape of research and clinical trials within the field
  • Based on therapeutic application, the other therapeutic segment including diseases such as blood disorders, and neurological disorders led the market with the largest revenue share of 72.75% in 2023, fueled by ongoing research and clinical advancements
  • North America dominated the market with the largest revenue share of 50.11% in 2023 and is anticipated to grow at the fastest CAGR of 28.07% during the forecast period, driven by several key factors. The market growth is facilitated by favorable regulatory frameworks, rising rates of chronic diseases, and technological improvements

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
    • 1.2.1. Therapy Type
    • 1.2.2. Therapeutic Application
  • 1.3. Information analysis
  • 1.4. Market formulation & data visualization
  • 1.5. Data validation & publishing
  • 1.6. Information Procurement
    • 1.6.1. Primary Research
  • 1.7. Information or Data Analysis
  • 1.8. Market Formulation & Validation
  • 1.9. Market Model
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Growing research & development in stem cell therapy
      • 3.2.1.2. Increasing prevalence of chronic diseases
      • 3.2.1.3. Technological advancements
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High cost of stem cell therapy
  • 3.3. Industry Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Stem Cell Therapy Market: Therapy Type Business Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Stem Cell Therapy Market Therapy Type Movement Analysis
  • 4.3. Global Stem Cell Therapy Market Size & Trend Analysis, by Therapy Type, 2018 to 2030 (USD Million)
  • 4.4. Allogeneic Stem Cell Therapies
    • 4.4.1. Global Allogeneic Stem Cell Therapies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.2. Hematopoietic Stem Cell Therapies
      • 4.4.2.1. Global Hematopoietic Stem Cell Therapies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.3. Mesenchymal Stem Cell Therapies
      • 4.4.3.1. Global Mesenchymal Stem Cell Therapies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Autologous Stem Cell Therapies, by Type
    • 4.5.1. Global Autologous Stem Cell Therapies, by Type Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.2. BM, Blood, & Umbilical Cord-derived Stem Cells
      • 4.5.2.1. Global BM, Blood, & Umbilical Cord-derived Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.3. Adipose-Derived Cells
      • 4.5.3.1. Global Adipose-Derived Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.4. Others
      • 4.5.4.1. Global Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Stem Cell Therapy Market: Therapeutic Application Business Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Stem Cell Therapy Market Therapeutic Application, Movement Analysis
  • 5.3. Global Stem Cell Therapy Market Size & Trend Analysis, by Therapeutic Application, 2018 to 2030 (USD Million)
  • 5.4. Oncology
    • 5.4.1. Global Oncology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Cardiovascular Disease (CVD)
    • 5.5.1. Global Cardiovascular Disease (CVD) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Musculoskeletal Disorders
    • 5.6.1. Global Musculoskeletal Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Global Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Stem Cell Therapy Market: Regional Estimates & Trend Analysis by Therapy Type, and Therapeutic Application

  • 6.1. Regional Dashboard
  • 6.2. Market Size & Forecasts and Trend Analysis, 2018 to 2030
  • 6.3. North America
    • 6.3.1. North America Stem Cell Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.2. U.S.
      • 6.3.2.1. Key Country Dynamics
      • 6.3.2.2. Competitive Scenario
      • 6.3.2.3. Regulatory Framework
      • 6.3.2.4. U.S. Stem Cell Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.3. Canada
      • 6.3.3.1. Key Country Dynamics
      • 6.3.3.2. Competitive Scenario
      • 6.3.3.3. Regulatory Framework
      • 6.3.3.4. Canada Stem Cell Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Europe
    • 6.4.1. Europe Stem Cell Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.2. UK
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Competitive Scenario
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. UK Stem Cell Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Germany
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Competitive Scenario
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Germany Stem Cell Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. Switzerland
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Competitive Scenario
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Switzerland Stem Cell Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Asia Pacific Stem Cell Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. Japan
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Competitive Scenario
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Japan Stem Cell Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. China
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Competitive Scenario
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. China Stem Cell Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. India
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Competitive Scenario
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. India Stem Cell Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.5. South Korea
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Competitive Scenario
      • 6.5.5.3. Regulatory Framework
      • 6.5.5.4. South Korea Stem Cell Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Rest of World
    • 6.6.1. Rest of World Stem Cell Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Categorization
  • 7.2. Strategy Mapping
  • 7.3. Company Market Position Analysis, 2023
  • 7.4. Participant's Overview
    • 7.4.1. Bluebird Bio, Inc.
      • 7.4.1.1. Overview
      • 7.4.1.2. Financial Performance
      • 7.4.1.3. Product Benchmarking
      • 7.4.1.4. Strategic Initiatives
    • 7.4.2. NIPRO
      • 7.4.2.1. Overview
      • 7.4.2.2. Financial Performance
      • 7.4.2.3. Product Benchmarking
      • 7.4.2.4. Strategic Initiatives
    • 7.4.3. Orchard Therapeutics plc
      • 7.4.3.1. Overview
      • 7.4.3.2. Financial Performance
      • 7.4.3.3. Product Benchmarking
      • 7.4.3.4. Strategic Initiatives
    • 7.4.4. Pharmicell Co., Ltd.
      • 7.4.4.1. Overview
      • 7.4.4.2. Financial Performance
      • 7.4.4.3. Product Benchmarking
      • 7.4.4.4. Strategic Initiatives
    • 7.4.5. CorestemChemon Inc.
      • 7.4.5.1. Overview
      • 7.4.5.2. Financial Performance
      • 7.4.5.3. Product Benchmarking
      • 7.4.5.4. Strategic Initiatives
    • 7.4.6. ANTEROGEN.CO.,LTD.
      • 7.4.6.1. Overview
      • 7.4.6.2. Financial Performance
      • 7.4.6.3. Product Benchmarking
      • 7.4.6.4. Strategic Initiatives
    • 7.4.7. Holostem S.r.l.
      • 7.4.7.1. Overview
      • 7.4.7.2. Financial Performance
      • 7.4.7.3. Product Benchmarking
      • 7.4.7.4. Strategic Initiatives
    • 7.4.8. Vertex Pharmaceuticals, Inc.
      • 7.4.8.1. Overview
      • 7.4.8.2. Financial Performance
      • 7.4.8.3. Product Benchmarking
      • 7.4.8.4. Strategic Initiatives
    • 7.4.9. Cleveland Cord Blood Center
      • 7.4.9.1. Overview
      • 7.4.9.2. Financial Performance
      • 7.4.9.3. Product Benchmarking
      • 7.4.9.4. Strategic Initiatives
    • 7.4.10. Gamida Cell Ltd.
      • 7.4.10.1. Overview
      • 7.4.10.2. Financial Performance
      • 7.4.10.3. Product Benchmarking
      • 7.4.10.4. Strategic Initiatives